RayKnowChina Research Map
Shortlist

WuhanWuhan University

Zhongnan Hospital of Wuhan University

武汉大学中南医院

Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongnan Hospital of Wuhan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌11 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌2 papers led
  3. Hepatocellular carcinoma肝细胞癌97 papers led
  4. Stomach cancer胃癌29 papers led2 open trials led
  5. Retinoblastoma视网膜母细胞瘤2 papers led
  6. Osteosarcoma骨肉瘤19 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  8. Neuroblastoma神经母细胞瘤6 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤12 papers led3 open trials led
  11. Aplastic anaemia再生障碍性贫血2 papers led
  12. Fanconi anaemia范可尼贫血2 papers led
  13. Moyamoya disease烟雾病13 papers led
  14. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  15. Takayasu arteritis大动脉炎1 paper led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化6 papers led
  17. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  18. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  19. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  20. Behçet disease白塞病2 papers led
  21. IgA nephropathyIgA 肾病1 paper led
  22. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  23. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  24. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 11 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 4420242025: 112025

6 hospitals in Wuhan for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  2. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  3. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImmunotherapy
Departments in papersPathology / laboratory medicineENT / head & neck surgeryMedical oncologyRadiology / nuclear medicine
Papers it led11
  1. Spatial Metabolomics and Transcriptomics Reveal Metabolic Reprogramming and Cellular Interactions in Nasopharyngeal Carcinoma with High PD-1 Expression and Therapeutic Response.2025TheranosticsFree full text
  2. Fluoroscopy-Guided Balloon Dilation for Severe Nasopharyngeal Stenosis Resulting from Radiotherapy for Nasopharyngeal Carcinoma.2024Cardiovascular and interventional radiology
  3. Intratumoral microbiota associates with systemic immune inflammation state in nasopharyngeal carcinoma.2024International immunopharmacology
  4. Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma.2024Neoplasia (New York, N.Y.)Free full text
  5. Implications of ITCH-mediated ubiquitination of SIX1 on CDC27-cyclinB1 signaling in nasopharyngeal carcinoma.2024Scientific reportsFree full text
  6. Exploration of spatial heterogeneity of tumor microenvironment in nasopharyngeal carcinoma via transcriptional digital spatial profiling.2023International journal of biological sciencesFree full text
  7. Knockdown of MTHFD2 inhibits proliferation and migration of nasopharyngeal carcinoma cells through the ERK signaling pathway.2022Biochemical and biophysical research communications
  8. LINC00324 suppresses apoptosis and autophagy in nasopharyngeal carcinoma through upregulation of PAD4 and activation of the PI3K/AKT signaling pathway.2022Cell biology and toxicology
  9. Cuproptosis related genes associated with Jab1 shapes tumor microenvironment and pharmacological profile in nasopharyngeal carcinoma.2022Frontiers in immunologyFree full text
  10. Oral pH value predicts the incidence of radiotherapy related caries in nasopharyngeal carcinoma patients.2021Scientific reportsFree full text
  11. Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status5
  1. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  2. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  3. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  4. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  5. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRTStatus unknownNCT01817023Study sitePhase 3Start 2013-04
More papers found outside PubMed (not counted)9
  1. Development and Validation of a Multi‐Omics Model Integrating MR Radiomics and Immune Scores for Prognostic Prediction in Locally Advanced Nasopharyngeal Carcinoma2025Flavour and Fragrance Journalarticle
  2. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computingarticle
  3. Differential sensitivities of primary tumor and lymph nodes to induction chemotherapy and definitive radiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  4. Targeting the JAK1 /STAT3 Signaling Pathway: Entinostat as a Promising Treatment for Nasopharyngeal Carcinoma2024Research Squarepreprint
  5. Apatinib in recurrent or metastatic head and neck cancer patients.2022Journal of Clinical Oncologyconference-abstract
  6. Statistical process control tools for setup reproducibility in quality control practices during nasopharyngeal carcinoma radiotherapy2022Internatuinal Journal of Radiation Researcharticle
  7. Induction Cisplatin and Gemcitabine Versus Cisplatin, Fluorouracil, and Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma: a Network Meta-analysis2021Research Squarepreprint
  8. Prognostic value of tumour infiltrating lymphocytes in nasopharyngeal carcinoma patients: Meta-Analysis2021Venue not listedstudy-registration
  9. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 2 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

5 hospitals in Wuhan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led2
  1. RIG-I promotes cell proliferation in esophageal squamous cell carcinoma by facilitating p21 degradation.2023Medical oncology (Northwood, London, England)
  2. JUND facilitates proliferation and angiogenesis of esophageal squamous cell carcinoma cell via MAPRE2 up-regulation.2023Tissue & cell
All its trials on ClinicalTrials.gov, any status2
  1. The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal CancerCompletedNCT04212598Lead (inferred)Phase 2Start 2020-08
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
More papers found outside PubMed (not counted)7
  1. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  3. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  4. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  5. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  6. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  7. Relationship between ENO1 and Metastasis Risk and Prognosis in Esophageal squamous cell carcinoma2022Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 97 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
97
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 161620212022: 131320222023: 212120232024: 191920242025: 26262025

6 hospitals in Wuhan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led97
  1. A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.2026Journal of hepatology
  2. Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC.2026Trends in endocrinology and metabolism: TEM
  3. Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine for Tumor Immunotherapy and Recurrence Prevention.2025ACS nano
  4. β-Glucan nanotubes loaded with iron diselenide for enhanced photothermal and photodynamic therapy in hepatocellular carcinoma.2025Acta biomaterialia
  5. Proteolysis-triggered RNA Interference for Mitochondrial Iron Dyshomeostasis to Activate Antitumor Immunity in Hepatic Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  6. PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  7. Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: A Meta-Analysis.2025BMC cancerFree full text
  8. Mesoporous cerium oxide nanoenzyme for Efficacious impeding tumor and metastasis via Conferring resistance to anoikis.2025Biomaterials
  9. Structurally diverse tetrahydroxanthone analogues from Paraconiothyrium sp. AC31 with pyroptosis induction through targeted inhibition of PARP1 in hepatocellular carcinoma cells.2025Bioorganic chemistry
  10. Tidal microfluidic chip-based isolation and transcriptomic profiling of plasma extracellular vesicles for clinical monitoring of high-risk patients with hepatocellular carcinoma-associated precursors.2025Biosensors & bioelectronics
  11. RNF5 exacerbates steatotic HCC by enhancing fatty acid oxidation via the improvement of CPT1A stability.2025Cancer letters
  12. Bioinformatics Identification of Lactate-Associated Genes in Hepatocellular Carcinoma: G6PD's Role in Immune Modulation.2025Cancer medicineFree full text
  13. The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma.2025Cancer research
  14. UBE2Q2 promotes tumor progression and glycolysis of hepatocellular carcinoma through NF-κB/HIF1α signal pathway.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  15. HBV upregulates TNNT1 expression through PI3K/AKT/mTOR-c-Myc axis, which in turn induces EMT and liver fibrosis in mice.2025Cellular signalling
  16. Impact of single-cell cell cycle regulation of intercellular communication on the prognosis of hepatocellular carcinoma in the tumor microenvironment.2025Clinical and experimental medicineFree full text
  17. Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study.2025Clinical epigeneticsFree full text
  18. Noninvasive prediction model for predicting spontaneous tumor necrosis in hepatocellular carcinoma and prognostic study.2025European journal of gastroenterology & hepatologyFree full text
  19. Blocking Tim-3 enhances CD8+ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  20. Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.2025JCI insightFree full text
  21. MEF2D regulates T-cell function via CD70-CD27 signaling and promotes immune evasion in hepatocellular carcinoma.2025Journal of immunology (Baltimore, Md. : 1950)
  22. 3D dynamic magnetic microfluidic chip for efficient plasma extracellular vesicle enrichment and machine learning-based multiparametric diagnosis of hepatocellular carcinoma.2025Journal of nanobiotechnologyFree full text
  23. LncRNA PVT1 activated by TGF-β1/Smad3 facilitates proliferation and metastasis of hepatocellular carcinoma via upregulating Smad6 and NRG1.2025Journal of translational medicineFree full text
  24. ADH1C maintains the homeostasis of metabolic microenvironment to inhibit steatotic hepatocellular carcinoma.2025Metabolism: clinical and experimental
  25. WDR4 drives tumour-associated macrophage reprogramming and tumour progression via selective translation and membrane cholesterol efflux.2025Nature cell biology
  26. Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma.2025PeerJFree full text
  27. CircRNA ZFR promotes cell progression by regulating miR-96a-5p/SLC1A1 axis in hepatocellular carcinoma.2025Scientific reportsFree full text
  28. Plasma proteomic analysis reveals altered protein abundances in HIV/HBV co-infection individuals with HCC and with liver cirrhosis.2025Scientific reportsFree full text
  29. The potential of 18F-FDG PET/CT metabolic parameter-based nomogram in predicting the microvascular invasion of hepatocellular carcinoma before liver transplantation.2024Abdominal radiology (New York)
  30. Photothermal Fibrous Chitosan/Polydopamine Sponge for Intraoperative Hemostasis and Prevention of Tumor Recurrence in Hepatocellular Carcinoma Resection.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  31. Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8+ T Cell Activation and Allow Tumor Immune Escape.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  32. Transcriptomic Signature of 3D Hierarchical Porous Chip Enriched Exosomes for Early Detection and Progression Monitoring of Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  33. Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma.2024Annals of hepatology
  34. Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development.2024Cancer research
  35. ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma.2024Cell reports
  36. OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  37. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma.2024Computers in biology and medicine
  38. Nomogram predicting survival in patients with lymph node-negative hepatocellular carcinoma based on the SEER database and external validation.2024European journal of gastroenterology & hepatologyFree full text
  39. A m6A regulators-related classifier for prognosis and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  40. Dynamic regulation of EXO1 promotes the progression from liver fibrosis to HCC through TGF-β1/Smad signaling feedback loop.2024Hepatology communicationsFree full text
  41. Cabozantinib as the first step toward postimmunotherapy treatment in hepatocellular carcinoma.2024Journal of surgical oncology
  42. Genetic evidence of the causal relationship between chronic liver diseases and musculoskeletal disorders.2024Journal of translational medicineFree full text
  43. Construction and validation of a nomogram for predicting cancer-specific survival in middle-aged patients with advanced hepatocellular carcinoma: A SEER-based study.2024MedicineFree full text
  44. RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4.2024Oncogene
  45. TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation.2024Oncogene
  46. DAB2 + macrophages support FAP + fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer.2024TheranosticsFree full text
  47. B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma.2024World journal of gastroenterologyFree full text
  48. Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation- Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study.2023Annals of surgical oncologyFree full text
  49. Mechanism underlying the effect of Pulsatilla decoction in hepatocellular carcinoma treatment: a network pharmacology and in vitro analysis.2023BMC complementary medicine and therapiesFree full text
  50. Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening.2023BioMed research internationalFree full text
  51. FKBP11 upregulation promotes proliferation and migration in hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markersFree full text
  52. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.2023Cancer communications (London, England)Free full text
  53. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.2023Cancer medicineFree full text
  54. Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma.2023CellsFree full text
  55. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-boxFBXO11 -mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma.2023Clinical and translational medicineFree full text
  56. GSPT1 Functions as a Tumor Promoter in Human Liver Cancer.2023Current medical science
  57. High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma.2023Current medical science
  58. Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry.2023Frontiers in immunologyFree full text
  59. FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.2023International journal of biological sciencesFree full text
  60. Genome stability‑related lncRNA ZFPM2‑AS1 promotes tumor progression via miR‑3065‑5p/XRCC4 in hepatocellular carcinoma.2023International journal of oncologyFree full text
  61. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  62. Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis.2023Journal of translational medicineFree full text
  63. Circ_0007429/miR-637/TRIM71/Ago2 axis participates in the regulation of proliferation, migration, invasion, apoptosis, and aerobic glycolysis of HCC.2023Molecular carcinogenesis
  64. Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma.2023Molecules (Basel, Switzerland)Free full text
  65. ncRNA-mediated fatty acid metabolism reprogramming in HCC.2023Trends in endocrinology and metabolism: TEM
  66. Alternative splicing: a bridge connecting NAFLD and HCC.2023Trends in molecular medicine
  67. Advances in biomarker discovery using circulating cell-free DNA for early detection of hepatocellular carcinoma.2023WIREs mechanisms of diseaseFree full text
  68. Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma.2023World journal of gastroenterologyFree full text
  69. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  70. Upregulation of the long non-coding RNA, LIPCAR promotes proliferation, migration, and metastasis of hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markersFree full text
  71. DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication.2022Cancer scienceFree full text
  72. NUP153 promotes HCC cells proliferation via c-Myc-mediated downregulation of P15INK4b.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  73. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.2022Digestive diseases and sciences
  74. Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways.2022International journal of biological sciencesFree full text
  75. A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma.2022International journal of biological sciencesFree full text
  76. Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1.2022International journal of biological sciencesFree full text
  77. Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism.2022International journal of biological sciencesFree full text
  78. Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene.2022Medical oncology (Northwood, London, England)Free full text
  79. A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression.2022Molecular metabolismFree full text
  80. A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma.2022Scientific reportsFree full text
  81. Indocyanine green fluorescence imaging-guided laparoscopic right posterior hepatectomy.2022Surgical endoscopy
  82. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress.2021AgingFree full text
  83. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.2021BMC cancerFree full text
  84. Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.2021BMC cancerFree full text
  85. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.2021Cancer chemotherapy and pharmacology
  86. lncRNA SNHG6 promotes hepatocellular carcinoma progression by interacting with HNRNPL/PTBP1 to facilitate SETD7/LZTFL1 mRNA destabilization.2021Cancer letters
  87. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4.2021Cancer letters
  88. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  89. Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathways.2021Cell death & diseaseFree full text
  90. miR-143-3p inhibits proliferation and invasion of hepatocellular carcinoma cells by regulating its target gene FGF1.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  91. MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting HIF1α Under Hypoxia.2021Digestive diseases and sciences
  92. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis.2021Epigenomics
  93. Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC.2021Human cell
  94. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival.2021International journal of biological sciencesFree full text
  95. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  96. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.2021Journal of immunology researchFree full text
  97. Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs.2021Journal of medicinal chemistry
All its trials on ClinicalTrials.gov, any status15
  1. Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular CarcinomaStatus unknownNCT05575622Lead sponsorStart 2023-01
  2. Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05282433Lead sponsorPhase 2Start 2022-04
  3. Clinical Study of MAK Immune Cells in the Treatment of PHCStatus unknownNCT05242757Lead sponsorN/AStart 2021-01
  4. Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver CancerStatus unknownNCT04688606Lead sponsorStart 2020-01
  5. High Dose Vitamin C Combined With Metformin in the Treatment of Malignant TumorsStatus unknownNCT04033107Lead sponsorPhase 2Start 2020-07
  6. Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune MicroenvironmentStatus unknownNCT05677724Lead (inferred)Start 2022-07
  7. Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic MalignanciesStatus unknownNCT05240690Lead (inferred)Phase 1Start 2022-02
  8. A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.CompletedNCT06626724Lead (inferred)Start 2020-01
  9. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  10. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Study sitePhase 2Start 2023-06
  11. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  12. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  13. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  14. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  15. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 29 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
29
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 101020222023: 3320232024: 5520242025: 332025

5 hospitals in Wuhan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06464601

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  2. Not yet recruiting
    A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06496919

    Age 18 years to 80 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologyMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led29
  1. PRDM15 inhibits responses of Tissue-Resident memory T cells by activating PVR/TIGIT axis to mediate gastric cancer immunosuppression.2026Journal of advanced researchFree full text
  2. Myeloid-Derived LGALS9-P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism.2025Journal of cellular and molecular medicineFree full text
  3. Crosstalk Between Gastric Cancer and Adjacent Mucosa Reveals EDN1-EDNRA-Mediated Regulation of Cancer Stemness and Immunomodulation Networks.2025Journal of cellular and molecular medicineFree full text
  4. TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer.2025Molecular and cellular biochemistry
  5. Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.2024Drug design, development and therapyFree full text
  6. Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer.2024International immunopharmacology
  7. Development and Validation of a Comprehensive Prognostic and Depression Risk Index for Gastric Adenocarcinoma.2024International journal of molecular sciencesFree full text
  8. NF1 mutation and TUBB3 amplification in gastric histiocytic sarcoma: a case report and literature review.2024Medical molecular morphology
  9. The mechanism of RGS5 regulating gastric cancer mismatch repair protein.2024Molecular carcinogenesis
  10. Upregulation of LINC00501 by H3K27 acetylation facilitates gastric cancer metastasis through activating epithelial-mesenchymal transition and angiogenesis.2023Clinical and translational medicineFree full text
  11. BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer.2023International journal of biological sciencesFree full text
  12. Comprehensive analysis of cuproptosis-related genes in prognosis, tumor microenvironment infiltration, and immunotherapy response in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  13. Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.2022BMC gastroenterologyFree full text
  14. Primary ovarian carcinoid arising in associated mature cystic teratoma.2022BMC women's healthFree full text
  15. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2.2022Cell death & diseaseFree full text
  16. MiR-192-5p/RB1/NF-κBp65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment.2022Clinical and translational medicineFree full text
  17. Bioinformatics Analysis and Identification of Potential Genes Associated with Pathogenesis and Prognosis of Gastric Cancer.2022Current medical science
  18. LAMC1-mediated preadipocytes differentiation promoted peritoneum pre-metastatic niche formation and gastric cancer metastasis.2022International journal of biological sciencesFree full text
  19. The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination.2022International journal of biological sciencesFree full text
  20. Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR-1294 to target pre-leukemia transcription factor 3.2022Journal of clinical laboratory analysisFree full text
  21. The lncRNA SEMA3B-AS1/HMGB1/FBXW7 Axis Mediates the Peritoneal Metastasis of Gastric Cancer by Regulating BGN Protein Ubiquitination.2022Oxidative medicine and cellular longevityFree full text
  22. Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer.2022Redox biologyFree full text
  23. Circular RNA circ_0000423 promotes gastric cancer cell proliferation, migration and invasion via the microR-582-3p/Disheveled-Axin domain containing 1 axis.2021BioengineeredFree full text
  24. The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development.2021BioengineeredFree full text
  25. Circular RNA hsa_circ_0000751 serves as a microRNA-488 sponge to suppress gastric cancer progression via ubiquinol-cytochrome c reductase core protein 2 regulation.2021BioengineeredFree full text
  26. Adenocarcinoma with Mixed Subtypes in the Early and Advanced Gastric Cancer.2021Canadian journal of gastroenterology & hepatologyFree full text
  27. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.2021Cancer medicineFree full text
  28. Magnifying endoscopy in detecting early gastric cancer: A network meta-analysis of prospective studies.2021MedicineFree full text
  29. Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer: A meta-analysis.2021Pharmacological research
Chinese-language papers (not in the count)1
  1. [Immune-related genes and their determined immune cell microenvironment to predict the prognosis of gastric adenocarcinoma].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status12
  1. High Dose Vitamin C Combined With Metformin in the Treatment of Malignant TumorsStatus unknownNCT04033107Lead sponsorPhase 2Start 2020-07
  2. Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical ResectionStatus unknownNCT03392103Lead sponsorPhase 2Start 2017-01
  3. A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric CancerNot yet recruitingNCT06464601Lead (inferred)Start 2025-04
  4. A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant TumorsNot yet recruitingNCT06496919Lead (inferred)Start 2024-08
  5. The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric CancerStatus unknownNCT03154983Lead (inferred)Phase 2Start 2017-05
  6. Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric CancerCompletedNCT02528110Lead (inferred)Phase 2Start 2015-08
  7. Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric CancerStatus unknownNCT01889303Lead (inferred)Phase 2Start 2013-05
  8. Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal CarcinomatosisStatus unknownNCT00454519Lead (inferred)Phase 2Start 2007-03
  9. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  10. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  11. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04
  12. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

16 hospitals in Wuhan for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 19 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 5520232024: 2220242025: 442025

22 hospitals in Wuhan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led19
  1. Trimerization-Enhanced NIR-II/Photoacoustic Nanoprobes for Precision Osteosarcoma Imaging.2025Analytical chemistry
  2. Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.2025BMC cancer
  3. Near-infrared light-enhanced polydopamine-based multifunctional nanoparticles for combination of chemodynamic and NO gas therapy in the treatment of osteosarcoma.2025International journal of biological macromolecules
  4. HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway.2025Journal of cellular and molecular medicine
  5. Bone Destruction-Chemotactic Osteoprogenitor Cells Deliver Liposome Nanomedicines for the Treatment of Osteosarcoma and Osteoporosis.2024ACS nano
  6. Metastatic dedifferentiated liposarcoma of the mediastinum with osteosarcomatous differentiation: A case report.2024Medicine
  7. Autophagy and its role in osteosarcoma.2023Cancer medicine
  8. NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m5C methylation.2023Cell death & disease
  9. Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway.2023Clinical and experimental medicine
  10. Aa-Z2 triggers ROS-induced apoptosis of osteosarcoma by targeting PDK-1.2023Journal of translational medicine
  11. 3-AP inhibits the growth of human osteosarcoma by decreasing the activity of the iron-dependent pathway.2023Medical oncology (Northwood, London, England)
  12. Nigericin exerts anticancer effects through inhibition of the SRC/STAT3/BCL-2 in osteosarcoma.2022Biochemical pharmacology
  13. Peptide-based semiconducting polymer nanoparticles for osteosarcoma-targeted NIR-II fluorescence/NIR-I photoacoustic dual-model imaging and photothermal/photodynamic therapies.2022Journal of nanobiotechnology
  14. Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.2022Medical oncology (Northwood, London, England)
  15. Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis.2021Biochemical and biophysical research communications
  16. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor.2021Journal of controlled release : official journal of the Controlled Release Society
  17. EWS-FLI1-targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near-infrared imaging.2021Molecular oncology
  18. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.2021Oxidative medicine and cellular longevity
  19. In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.2021Theranostics
Earlier papers (2016–2020)12
  1. Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo.2020Nanomedicine (London, England)
  2. Overexpression of miR-335 inhibits the migration and invasion of osteosarcoma by targeting SNIP1.2019International journal of biological macromolecules
  3. Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.2018Drug metabolism and disposition: the biological fate of chemicals
  5. L‑mimosine induces caspase‑9‑mediated apoptosis in human osteosarcoma cells.2018Molecular medicine reports
  6. Survival outcome among patients with Ewing's sarcoma of bones and joints: a population-based cohort study.2018Sao Paulo medical journal = Revista paulista de medicina
  7. HIF-1α inhibits IDH-1 expression in osteosarcoma.2017Oncology reports
  8. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.2017Oncotarget
  9. MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.2017Scientific reports
  10. miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells.2016Bioscience reports
  11. Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-κB and MMP-9 activation.2016Oncology reports
  12. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

9 hospitals in Wuhan for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 6 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 0020242025: 002025

10 hospitals in Wuhan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

6 hospitals in Wuhan for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 12 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.7%.

Papers led
12
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 2220232024: 4420242025: 112025

3 hospitals in Wuhan for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07305337

    Age 18 years to 90 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  2. Recruiting
    Helical Tomotherapy in Multiple Myeloma
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05970198

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  3. Enrolling by invitation
    AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
    Phase
    Not given
    Started
    2018-08
    Registry
    NCT07410403

    Age not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  4. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  5. Not yet recruiting
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06799676

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications
Papers it led12
  1. Compound Kushen Injection suppresses multiple myeloma progression via TOP1-targeted coordination of DNA damage and endoplasmic reticulum stress.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.2024Annals of hematology
  3. Clinical and immunological characteristics of high-risk double-hit multiple myeloma.2024BMC cancerFree full text
  4. The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study.2024Clinical and experimental medicineFree full text
  5. Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.2024Renal failureFree full text
  6. Global burden of hematologic malignancies and evolution patterns over the past 30 years.2023Blood cancer journalFree full text
  7. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.2023Journal of cancer research and clinical oncologyFree full text
  8. Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.2022Contrast media & molecular imagingFree full text
  9. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.2022Hematological oncology
  10. Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.2022Journal of immunology researchFree full text
  11. Management of acute spinal cord compression in multiple myeloma.2021Critical reviews in oncology/hematology
  12. Identification of novel combined biomarkers in the diagnosis of multiple myeloma.2021Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)1
  1. [Changes of Serum Complement C1q in Patients with Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status10
  1. Randomised Controlled Trial of Artificial Intelligence-assisted Health EducationRecruitingNCT07305337Lead sponsorN/AStart 2025-06
  2. Plasma-free Replacement in Patients With Multiple MyelomaCompletedNCT05251896Lead sponsorN/AStart 2020-01
  3. Helical Tomotherapy in Multiple MyelomaRecruitingNCT05970198Lead (inferred)N/AStart 2023-06
  4. AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH AbnormalitiesEnrolling by invitationNCT07410403Lead (inferred)Start 2018-08
  5. Double Filtration Plasmapheresis Combined With ChemotherapyStatus unknownNCT04836871Lead (inferred)Phase 1Start 2021-05
  6. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  7. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Study sitePhase 1/Phase 2Start 2025-02
  8. ATG-010(Selinexor) in Combination With Chemotherapy in RRMMStatus unknownNCT04877275Study sitePhase 2Start 2021-05
  9. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  10. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

4 hospitals in Wuhan for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 2 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 2.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Wuhan for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 13 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 3.6%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 4420232024: 5520242025: 112025

3 hospitals in Wuhan for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowChildren
Departments in papersNeurosurgery
Papers it led13
  1. Treatment strategies and prognostic analysis of moyamoya disease associated with single intracranial aneurysm.2025Clinical neurology and neurosurgery
  2. Association of retrograde bypass flow depth along cortical recipient arteries with revascularization outcomes in direct bypass surgery for Moyamoya disease.2024Clinical neurology and neurosurgery
  3. Intraoperative evaluation of local cerebral hemodynamic change by laser speckle contrast imaging for predicting postoperative cerebral hyperperfusion during STA-MCA bypass in adult patients with moyamoya disease.2024Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFree full text
  4. Role of scalp arteries in revascularization after side to side anastomosis in moyamoya disease patients.2024Scientific reportsFree full text
  5. Arterialized Vein Immediately After Direct Bypass Surgery Indicates Cerebral Hyperperfusion Syndrome in Moyamoya Disease.2024Stroke
  6. Treatment of moyamoya disease with intracranial aneurysm by surgical clipping combined with encephalo-duro-myo-synangiosis surgery: a case report and literature review.2024The International journal of neuroscience
  7. Increase in age at onset of moyamoya disease in China over 25 years.2023Brain and behaviorFree full text
  8. Assessment of plasma soluble Tie-2 level to distinguish moyamoya disease from atherosclerotic cerebrovascular disease and predict postoperative neovascularization.2023Journal of neurosurgery
  9. A flow self-regulating superficial temporal artery-middle cerebral artery bypass based on side-to-side anastomosis for adult patients with moyamoya disease.2023Journal of neurosurgery
  10. The Progression of Pathophysiology of Moyamoya Disease.2023Neurosurgery
  11. The contralateral progression in a cohort of Chinese adult patients with unilateral moyamoya disease after revascularization: a single-center long-term retrospective study.2022Acta neurochirurgicaFree full text
  12. How to choose the surgical side when cerebral blood flow and cerebrovascular response are contradictory in bilateral moyamoya disease?: A case report.2022MedicineFree full text
  13. An ecological comparison study on the causal association between leptospirosis and moyamoya disease in Hubei, China, 2017-2019.2021Clinical neurology and neurosurgery
All its trials on ClinicalTrials.gov, any status1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
More papers found outside PubMed (not counted)3
  1. Recent Advances for Global Perspectives on Etiology, Pathophysiology, Clinical Presentations, and Management of Moyamoya Disease2024World Journal of Neurosciencearticle
  2. An Ecological Comparison Study On The Causal Association Between Leptospirosis and Moyamoya Disease in Hubei, China, 2017-20192021Research Squarepreprint
  3. The Association Between RNF213 , MMP3 , and Moyamoya Disease: Screening the Full Exons of Susceptibility Genes in Families with Moyamoya Disease2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

5 hospitals in Wuhan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Wuhan for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Ischemic stroke as the first manifestation of Takayasu arteritis: high resolution magnetic resonance imaging.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 6 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 332025

9 hospitals in Wuhan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wuhan for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Sporadic lymphangioleiomyomatosis with multiple atypical features: A case report and literature review.2018Indian journal of pathology & microbiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Wuhan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Wuhan for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

7 hospitals in Wuhan for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

8 hospitals in Wuhan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.2021International urology and nephrology
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Wuhan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Wuhan for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Wuhan for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

武汉大学中南医院

Zhongnan Hospital of Wuhan University

武汉

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Zhongnan Hospital; Wuhan University Zhongnan Hospital; Zhongnan hospital of Wuhan University

Suggest a correctionDownload the data